TY - JOUR
T1 - Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?
AU - Speeckaert, Marijn
AU - Van Biesen, Wim
AU - Delanghe, Joris
AU - Slingerland, Robbert
AU - Wiecek, Andrej
AU - Heaf, James
AU - Drechsler, Christiane
AU - Lacatus, Raluca
AU - Vanholder, Raymond
AU - Nistor, Ionut
AU - European Renal Best Practice Guideline Development Group on Diabetes in Advanced CKD
N1 - © The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
PY - 2014/12
Y1 - 2014/12
N2 - BACKGROUND: Although measurement of haemoglobin A1c has become the cornerstone for diagnosing diabetes mellitus in routine clinical practice, the role of this biomarker in reflecting long-term glycaemic control in patients with chronic kidney disease has been questioned.METHODS: Consensus review paper based on narrative literature review.RESULTS: As a different association between glycaemic control and morbidity/mortality might be observed in patients with and without renal insufficiency, the European Renal Best Practice, the official guideline body of the European Renal Association-European Dialysis and Transplant Association, presents the current knowledge and evidence of the use of alternative glycaemic markers (glycated albumin, fructosamine, 1,5-anhydroglucitol and continuous glucose monitoring).CONCLUSION: Although reference values of HbA1C might be different in patients with chronic kidney disease, it still remains the cornerstone as follow-up of longer term glycaemic control, as most clinical trials have used it as reference.
AB - BACKGROUND: Although measurement of haemoglobin A1c has become the cornerstone for diagnosing diabetes mellitus in routine clinical practice, the role of this biomarker in reflecting long-term glycaemic control in patients with chronic kidney disease has been questioned.METHODS: Consensus review paper based on narrative literature review.RESULTS: As a different association between glycaemic control and morbidity/mortality might be observed in patients with and without renal insufficiency, the European Renal Best Practice, the official guideline body of the European Renal Association-European Dialysis and Transplant Association, presents the current knowledge and evidence of the use of alternative glycaemic markers (glycated albumin, fructosamine, 1,5-anhydroglucitol and continuous glucose monitoring).CONCLUSION: Although reference values of HbA1C might be different in patients with chronic kidney disease, it still remains the cornerstone as follow-up of longer term glycaemic control, as most clinical trials have used it as reference.
U2 - 10.1093/ndt/gfu006
DO - 10.1093/ndt/gfu006
M3 - Journal article
C2 - 24470517
SN - 0931-0509
VL - 29
SP - 2167
EP - 2177
JO - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
IS - 12
ER -